Assessing the contribution of opioid- and dopamine-related genetic polymorphisms to the abuse liability of oxycodone

@article{Jones2019AssessingTC,
  title={Assessing the contribution of opioid- and dopamine-related genetic polymorphisms to the abuse liability of oxycodone},
  author={J. Jones and Mudassir Mumtaz and J. Manubay and S. Mogali and S. Comer},
  journal={Pharmacology Biochemistry and Behavior},
  year={2019},
  volume={186}
}
  • J. Jones, Mudassir Mumtaz, +2 authors S. Comer
  • Published 2019
  • Medicine
  • Pharmacology Biochemistry and Behavior
  • BACKGROUND Attempts to identify opioid users at increased risk of escalating to opioid use disorder have had limited success. Data from a variety of sources suggest that genetic variation may mediate the subjective response to opioid drugs, and therefore contribute to their abuse potential. The goal of the current study was to observe the relationship between select genetic polymorphisms and the subjective effects of oxycodone under controlled clinical laboratory conditions. METHODS Non… CONTINUE READING
    4 Citations

    References

    SHOWING 1-10 OF 60 REFERENCES
    A brief review of the genetics and pharmacogenetics of opioid use disorders
    • 28
    • PDF
    Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction.
    • C. Bond, K. S. Laforge, +10 authors L. Yu
    • Biology, Medicine
    • Proceedings of the National Academy of Sciences of the United States of America
    • 1998
    • 995
    • PDF
    Pharmacogenetic analysis of opioid dependence treatment dose and dropout rate
    • 10